Sanofi Genzyme Strategy, SWOT and Corporate Finance Report [Report Updated: 28082018] Prices from USD $175

18:54 EDT 28 Sep 2018 | BioPortfolio Reports

Sanofi Genzyme Strategy, SWOT and Corporate Finance Report


Sanofi Genzyme Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.

Key Highlights

Sanofi Genzyme Genzyme, a specialty care global business unit of Sanofi provides treatments with a focus on rare diseases, multiple sclerosis, immunology, and oncology. The major products of the company include Aldurazyme, Aubagio, Caprelsa tablets, Cerdelga capsules, Cerezyme, Clolar, Dupixent injection, Elitek, Eloxatin, Fabrazyme, Jevtana, Kevzara injection, Lemtrada, Lumizyme, Mozobil injection, Taxotere injection concentrate, Thymoglobulin, Thyrogen and ZALTRAP injection for intravenous infusion. The company also addresses the unmet needs in immune diseases including atopic dermatitis, rheumatoid arthritis, asthma, nasal polyposis, and eosinophilic esophagitis. The company primarily operates in the Americas and Europe. Genzyme is headquartered in Cambridge, Massachusetts, the US.


Detailed information on Sanofi Genzyme required for business and competitor intelligence needs

A study of the major internal and external factors affecting Sanofi Genzyme in the form of a SWOT analysis

An indepth view of the business model of Sanofi Genzyme including a breakdown and examination of key business segments

Intelligence on Sanofi Genzyme's mergers and acquisitions MandA, strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

News about Sanofi Genzyme, such as business expansion, restructuring, and contract wins

Large number of easytograsp charts and graphs that present important data and key trends

Reasons to buy

Gain understanding of Sanofi Genzyme and the factors that influence its strategies.

Track strategic initiatives of the company and latest corporate news and actions.

Assess Sanofi Genzyme as a prospective partner, vendor or supplier.

Support sales activities by understanding your customers' businesses better.

Stay up to date on Sanofi Genzyme's business structure, strategy and prospects.

Original Article: Sanofi Genzyme Strategy, SWOT and Corporate Finance Report [Report Updated: 28082018] Prices from USD $175


More From BioPortfolio on "Sanofi Genzyme Strategy, SWOT and Corporate Finance Report [Report Updated: 28082018] Prices from USD $175"

Quick Search


Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world. Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, o...